Boniva ad hyped efficacy: DDMAC

Share this article:
A print ad for Genentech's Boniva overstated the osteoporosis drug's efficacy, said the FDA's DDMAC in an untitled letter.
The agency took issue with the claim in the ad, which features Sally Field, that: “Studies show, after a year on Boniva, 9 out of 10 women stopped and reversed their bone loss.” The claim, said DDMAC, “is not supported by substantial evidence or substantial clinical experience” but rather “a per-protocol post-hoc responder analysis that the clinical study was not adequately designed to evaluate.” The ad that prompted the letter ran in Parade Magazine with the headline: “I wanted to stop my bone loss. But I did more. I reversed it with Boniva.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters